TipRanks

Notifications

Tag: IDXX

Total 95 Posts

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Idexx Laboratories (IDXXResearch Report), Bausch + Lomb Corporation (BLCOResearch Report) and Eli Lilly & Co (LLYResearch Report).

Idexx Laboratories (IDXX)

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Idexx Laboratories, with a price target of $655.00. The company’s shares closed last Friday at $576.29, close to its 52-week high of $579.68.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 3.9% and a 50.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.

Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $619.00.

See the top stocks recommended by analysts >>

Bausch + Lomb Corporation (BLCO)

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Bausch + Lomb Corporation, with a price target of $18.00. The company’s shares closed last Friday at $17.60.

According to TipRanks.com, Miksic is a 5-star analyst with an average return of 6.9% and a 63.2% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Edwards Lifesciences, and Baxter International.

Currently, the analyst consensus on Bausch + Lomb Corporation is a Moderate Buy with an average price target of $18.40, a 6.5% upside from current levels. In a report issued on February 21, Needham also maintained a Hold rating on the stock.

Eli Lilly & Co (LLY)

In a report issued on February 23, Carter Gould from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $810.00. The company’s shares closed last Friday at $769.54, close to its 52-week high of $794.47.

According to TipRanks.com, Gould is a 5-star analyst with an average return of 10.8% and a 58.3% success rate. Gould covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Travere Therapeutics, and Merck & Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $790.61 average price target, representing a 2.1% upside. In a report issued on February 9, TD Cowen also maintained a Buy rating on the stock with a $850.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IDXX:

Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Idexx Laboratories (IDXXResearch Report), Neurocrine (NBIXResearch Report) and Exelixis (EXELResearch Report).

Idexx Laboratories (IDXX)

Piper Sandler analyst David Westenberg maintained a Hold rating on Idexx Laboratories today and set a price target of $600.00. The company’s shares closed last Wednesday at $572.31, close to its 52-week high of $579.68.

According to TipRanks.com, Westenberg is a 4-star analyst with an average return of 4.1% and a 49.3% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Akoya Biosciences, and Cytek Biosciences.

Idexx Laboratories has an analyst consensus of Moderate Buy, with a price target consensus of $619.00, an 8.8% upside from current levels. In a report issued on February 5, Bank of America Securities also reiterated a Hold rating on the stock with a $600.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Neurocrine (NBIX)

Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Neurocrine yesterday and set a price target of $154.00. The company’s shares closed last Wednesday at $136.29, close to its 52-week high of $143.35.

According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 4.1% and a 42.5% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Bioxcel Therapeutics, and Zevra Therapeutics.

Neurocrine has an analyst consensus of Moderate Buy, with a price target consensus of $145.44, a 7.7% upside from current levels. In a report issued on January 23, Barclays also maintained a Buy rating on the stock with a $150.00 price target.

Exelixis (EXEL)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Exelixis, with a price target of $29.00. The company’s shares closed last Wednesday at $20.18.

According to TipRanks.com, Olson is a 5-star analyst with an average return of 13.1% and a 44.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Enanta Pharmaceuticals, and Crispr Therapeutics AG.

Exelixis has an analyst consensus of Strong Buy, with a price target consensus of $26.50, a 25.7% upside from current levels. In a report issued on January 25, Jefferies also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IDXX:

Morgan Stanley העלו את מחיר היעד שלהם עבור Idexx Laboratories מ-600 דולר ל-620 דולר ושומרים על דירוג קנייה למניה

לאחר רבעון רביעי חזק, הפירמה מאוד בטוחה שמטרות הכספיות החדשות של Idexx Laboratories לשנת הכספים 2024 הן ריאליסטיות ונקבעו בגישה מוקפדת. הם מציעים למשקיעים שתחזיות החברה מאפשרות את האפשרות לתוצאות